Business Wire

NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP

24.2.2026 14:00:00 CET | Business Wire | Press Release

Share

NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224427714/en/

Supporting stable, high-titer cell line development and seamless GMP advancement.

The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise including fill and finish, and regulatory quality. Together, the companies offer an integrated model that minimizes tech-transfer delays, reduces the risk of costly cell line rebuilds, and accelerates the path to IND-enabling and clinical material.

A Partnership Designed to Reduce Risk and Gain Time

The joint offering addresses some of the most common challenges faced by biotech companies: long development cycles, technical bottlenecks, and costly delays that impact valuation and fundraising timelines. By streamlining CLD and GMP manufacturing, customers gain a clear, uninterrupted path from early development to high-quality material suitable for clinical studies. For early-stage biotech companies operating against tight funding timelines, even a three-month delay can materially impact valuation and financing outcomes.

“Partnering with Demeetra strengthens our ability to support biotech companies all the way, with a rapid, reliable, and continuous path to GMP material,” said Janet Hoogstraate, CEO of NorthX Biologics. “Biotech companies no longer need to choose between best-in-class cell line development and proven GMP execution. Our collaboration with Demeetra provides an optimal solution for development of biologics.”

“We are excited to collaborate with NorthX Biologics,” said Jack Crawford, CEO of Demeetra. “Demeetra's platforms are designed to produce cell lines that go straight into manufacturing without rebuilds or licensing conversations downstream. Partnering with NorthX Biologics closes the loop. Together we've built a high-performance, end-to-end path that protects both the program timeline and the full economic value of the client’s asset.”

Key Customer Benefits

  • Royalty-free cell line development – molecule retains full economic value through fundraising, partnering or acquisition
  • A single, coordinated team – direct transition from CLD to GMP manufacturing with no re-qualification
  • Reduced technical and regulatory risk
  • Shorter timelines to IND/Phase I

The Demeetra and NorthX Biologics collaboration reflects a shared commitment to reducing fragmentation in early biologics development. By integrating genome engineering, cell line development, upstream processing, and GMP execution within a coordinated framework, the companies aim to simplify decision-making for biotech leaders and reduce the cumulative risk associated with multi-vendor handoffs.

About NorthX Biologics

NorthX Biologics is a leading contract development and manufacturing organization (CDMO) and Sweden’s national innovation hub for advanced biologics, enabling next-generation therapies beyond traditional manufacturing. With over 30 years of GMP experience, NorthX Biologics offers end-to-end services including process development, recombinant proteins, vaccines, viral vectors, cell therapies, and aseptic fill & finish. With its headquarters in Matfors, Sweden, and a facility in Stockholm, NorthX Biologics serves customers worldwide.

About Demeetra

Demeetra is a genome engineering company providing integrated platforms for gene editing, transposon-based integration, and cell line development. Demeetra’s technologies deliver high performance with clear intellectual property lineage, enabling confident adoption across research, development, and biomanufacturing workflows.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224427714/en/

Contacts

Janet Hoogstraate
Chief Executive Officer
Email: janet.hoogstraate@nxbio.com
Website: www.nxbio.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nxbio.com&e
sheet=54431808&newsitemid=20260224427714&lan=en-US&anchor=www.nxbio.com&index=4&
md5=87e1b4396b580df9f924192de9815376

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global and China Gas Announce Increased Long-Term LNG Agreement18.11.2026 01:00:00 CET | Press Release

Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of an increased Sales and Purchase Agreement (SPA) for the total purchase of 1.0 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement upsizes the previous SPA announced by the two parties in September 2026 for the purchase of 0.5 MTPA by another newly-agreed 0.5 MTPA. Venture Global’s total current long-term offtake with China Gas is now 3.0 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to continue growing our LNG partnership with China Gas, a leading natural gas operator in China, and help meet the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects,” said Venture Global CEO Mike Sabel. "We are pleased to further expa

UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press Release

UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products reach patients safely, reliably and when they’re needed,” said Wilfredo Ramos, UPS EVP and Chief International, H

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press Release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press Release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye